We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Zoetis (ZTS) Outperforms Broader Market: What You Need to Know
Read MoreHide Full Article
Zoetis (ZTS - Free Report) ended the recent trading session at $123.78, demonstrating a +1.26% change from the preceding day's closing price. This change outpaced the S&P 500's 0.64% gain on the day. Meanwhile, the Dow gained 0.47%, and the Nasdaq, a tech-heavy index, added 0.52%.
The stock of animal health company has risen by 0.15% in the past month, lagging the Medical sector's gain of 2.25% and the S&P 500's gain of 3%.
Analysts and investors alike will be keeping a close eye on the performance of Zoetis in its upcoming earnings disclosure. The company is forecasted to report an EPS of $1.4, showcasing no movement from the corresponding quarter of the prior year. Our most recent consensus estimate is calling for quarterly revenue of $2.36 billion, up 1.89% from the year-ago period.
ZTS's full-year Zacks Consensus Estimates are calling for earnings of $6.34 per share and revenue of $9.44 billion. These results would represent year-over-year changes of +7.09% and +2%, respectively.
Any recent changes to analyst estimates for Zoetis should also be noted by investors. Such recent modifications usually signify the changing landscape of near-term business trends. As a result, we can interpret positive estimate revisions as a good sign for the business outlook.
Empirical research indicates that these revisions in estimates have a direct correlation with impending stock price performance. To capitalize on this, we've crafted the Zacks Rank, a unique model that incorporates these estimate changes and offers a practical rating system.
The Zacks Rank system, spanning from #1 (Strong Buy) to #5 (Strong Sell), boasts an impressive track record of outperformance, audited externally, with #1 ranked stocks yielding an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate has moved 0.13% lower. As of now, Zoetis holds a Zacks Rank of #3 (Hold).
In terms of valuation, Zoetis is currently trading at a Forward P/E ratio of 19.3. This signifies a discount in comparison to the average Forward P/E of 19.43 for its industry.
Also, we should mention that ZTS has a PEG ratio of 2.66. The PEG ratio is similar to the widely-used P/E ratio, but this metric also takes the company's expected earnings growth rate into account. The Medical - Drugs was holding an average PEG ratio of 1.17 at yesterday's closing price.
The Medical - Drugs industry is part of the Medical sector. This group has a Zacks Industry Rank of 70, putting it in the top 29% of all 250+ industries.
The Zacks Industry Rank evaluates the power of our distinct industry groups by determining the average Zacks Rank of the individual stocks forming the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Ensure to harness Zacks.com to stay updated with all these stock-shifting metrics, among others, in the next trading sessions.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Zoetis (ZTS) Outperforms Broader Market: What You Need to Know
Zoetis (ZTS - Free Report) ended the recent trading session at $123.78, demonstrating a +1.26% change from the preceding day's closing price. This change outpaced the S&P 500's 0.64% gain on the day. Meanwhile, the Dow gained 0.47%, and the Nasdaq, a tech-heavy index, added 0.52%.
The stock of animal health company has risen by 0.15% in the past month, lagging the Medical sector's gain of 2.25% and the S&P 500's gain of 3%.
Analysts and investors alike will be keeping a close eye on the performance of Zoetis in its upcoming earnings disclosure. The company is forecasted to report an EPS of $1.4, showcasing no movement from the corresponding quarter of the prior year. Our most recent consensus estimate is calling for quarterly revenue of $2.36 billion, up 1.89% from the year-ago period.
ZTS's full-year Zacks Consensus Estimates are calling for earnings of $6.34 per share and revenue of $9.44 billion. These results would represent year-over-year changes of +7.09% and +2%, respectively.
Any recent changes to analyst estimates for Zoetis should also be noted by investors. Such recent modifications usually signify the changing landscape of near-term business trends. As a result, we can interpret positive estimate revisions as a good sign for the business outlook.
Empirical research indicates that these revisions in estimates have a direct correlation with impending stock price performance. To capitalize on this, we've crafted the Zacks Rank, a unique model that incorporates these estimate changes and offers a practical rating system.
The Zacks Rank system, spanning from #1 (Strong Buy) to #5 (Strong Sell), boasts an impressive track record of outperformance, audited externally, with #1 ranked stocks yielding an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate has moved 0.13% lower. As of now, Zoetis holds a Zacks Rank of #3 (Hold).
In terms of valuation, Zoetis is currently trading at a Forward P/E ratio of 19.3. This signifies a discount in comparison to the average Forward P/E of 19.43 for its industry.
Also, we should mention that ZTS has a PEG ratio of 2.66. The PEG ratio is similar to the widely-used P/E ratio, but this metric also takes the company's expected earnings growth rate into account. The Medical - Drugs was holding an average PEG ratio of 1.17 at yesterday's closing price.
The Medical - Drugs industry is part of the Medical sector. This group has a Zacks Industry Rank of 70, putting it in the top 29% of all 250+ industries.
The Zacks Industry Rank evaluates the power of our distinct industry groups by determining the average Zacks Rank of the individual stocks forming the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Ensure to harness Zacks.com to stay updated with all these stock-shifting metrics, among others, in the next trading sessions.